The Fibromyalgia Treatments Market Size was valued at USD 1.1 Billion in 2022 and is projected to grow and expand from USD 1.14 Billion in 2023 to USD 1.59 Billion by 2032, exhibiting a growth rate or CAGR (compound annual growth rate) of 4.2% during the forecast period (2023 - 2032).
Soft fibromyalgia therapy is used for its comfort and ability to cure numerous eye disorders, which are the key market drivers contributing to market growth and expansion.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Market CAGR for fibromyalgia treatments is driven by the rising ability to cure numerous eye disorders. Pharmacological side effects are the key factors hindering the growth of the thus market. According to the National Centre for Information on Biotechnology, antiepileptic medicines (AEDs) are psychotropic agents that impact the mind in both positive and bad ways, altering people's behavior. The side effects include migraines, diarrhea, lethargy, tremors, ataxia, vision impairment, and tremor. Sedation and weight gain can occur when tricyclic antidepressants are used with gabapentin. More serious adverse effects of pregabalin include skin blistering, peeling off or stretching, tightening in the chest, chest pain, and edema or inflammation of the lids or areas of the pupils, facial features, lips, or mouth. Established industry leaders are launching novel fibromyalgia therapies to build or maintain their market position. Impending fibromyalgia treatment releases and authorizations will drive market expansion throughout the forecast period.
Additionally, the worldwide growth of fibromyalgia is expected to boost the market. According to the NIAMS, about five million people in the United States aged 18 and up suffer from fibromyalgia. Furthermore, females account for 80% to 90% of people with fibromyalgia. Furthermore, rising government initiatives to educate businesses and healthcare providers about fibromyalgia are expected to boost market growth. For example, EULAR recommended using nonsteroidal anti-inflammatory in nature medicines (NSAID) to treat fibromyalgia in their 2016 recommendations. Such initiatives are expected to raise awareness and aid in managing fibromyalgia among those with the disease.
The unexpected breakout of COVID-19 in various countries has substantially impacted pharmaceutical businesses' income and operational capacities. Because fibromyalgia is a less commonly recognized and neglected condition, the decreased number of people seeking medical care for the disease due to the pandemic has had a detrimental influence on the market. Furthermore, the shift in focus of key actors toward manufacturing COVID-19 medication and prophylactic vaccinations has altered the supply and need for fibromyalgia therapy. The COVID-19 pandemic had an uncertain effect on the market, with the stress and uncertainty of the pandemic elevating fibromyalgia symptoms in people, increasing demand for medications. On the other hand, inadequate access to medical care and missed visits hampered fibromyalgia diagnosis and management.
For instance, according to the American College of Rheumatology, fibromyalgia is a chronic disorder that causes persistent pain and affects 2-4% of individuals worldwide. Furthermore, fibromyalgia has been more recognized and diagnosed, increasing the number of patients seeking therapy. As doctors and the general public become more aware of the illness, more people will be able to obtain a precise diagnosis and therapy for their symptoms of fibromyalgia. This growing incidence and knowledge are increasing the market share of fibromyalgia therapy. Thus, it is anticipated that demand for Fibromyalgia Treatments will increase throughout the projected timeframe due to the rising ability to cure numerous eye disorders. Thus, driving the Fibromyalgia Treatments market revenue.
The market segments of Fibromyalgia Treatments, based on Treatment, includes Antidepressants, Antiepileptics, Muscle Relaxants, And Others. The antiepileptic segment dominated the market, accounting for 35% of market revenue (USD 0.4 billion) in 2022. Although antiepileptic drugs are commonly used to treat epilepsy, it was additionally employed to treat fibromyalgia. The FDA has licensed the antiepileptic medicine pregabalin to treat fibromyalgia. Pregabalin inhibits the breakdown of P, norepinephrine, & glutamate, which may alleviate pain in people with fibromyalgia.
The Fibromyalgia Treatments market segmentation, based on End-Users, includes Hospitals and clinics. The hospital category Informatics category generated the highest market revenue of about 51% (USD 0.6 billion) in 2022. Examples include residential care facilities, outpatient clinics, hospitals, drug addiction treatment centers, poison control centers, and drug resource centers. In a medical environment, the work includes selecting, preparing, storing, mixing, and administering medications for patients.
Figure 1: Fibromyalgia Treatments Market by End-User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the research provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Fibromyalgia Treatments market area will dominate this market during the projected timeframe, owing to development due to a rise in fibromyalgia classifications and incidence, as well as the growing number of innovations approved by the FDA to treat the ailment, which will boost the market growth in the North American region.
Further, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Fibromyalgia Treatments Market Share by Region 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Revi
Europe region’s Fibromyalgia Treatments market accounts for the second-highest market share due to the Product releases and the lack of fibromyalgia therapies fueled market growth in the following years. Furthermore, it is expected that a rise in spending on healthcare by the European Commission will contribute to regional growth. Further, the German market of Fibromyalgia Treatments holds the largest market share, and the UK market of Fibromyalgia Treatments is expected to grow and expand significantly in the European region during the projected timeframe.
The Asia-Pacific Fibromyalgia Treatments Marketis expected to grow quickly during the projected timeframe. Factors such as a growing fibromyalgia patient population, increased healthcare spending, and advanced healthcare infrastructure are expected to favor market expansion in Asia-Pacific. Increasing fibromyalgia awareness is expected to boost the market over the projected period. Moreover, China’s market of Fibromyalgia Treatments dominates the market share, and the Indian market of Fibromyalgia Treatments is expected to expand and grow steadily in the Asia-Pacific region during the projected timeframe.
Fibromyalgia Treatments Key Market Players & Competitive Insights
Leading market players invested heavily in research and Development (R&D) to scale up their manufacturing units and develop technologically advanced solutions, which will help the market of Fibromyalgia Treatments grow worldwide. Market participants are also undertaking various organic or inorganic strategic approaches to strengthen and expand their footprint, with significant market developments including new product portfolios, contractual deals, mergers and acquisitions, capital expenditure, higher investments, and strategic alliances with other organizations. Businesses are also coming up with marketing strategies such as digital marketing, social media influencing, and content marketing to increase their scope of profit earnings. The Fibromyalgia Treatments industry must offer cost-effective and sustainable options to survive in a highly fragmented and dynamic market climate.
Manufacturing locally to minimize operational expenses and offer aftermarket services to customers is one of the critical business strategies organizations use in the Fibromyalgia Treatments industry to benefit customers and capture untapped market share and revenue. The Fibromyalgia Treatments industry has recently offered significant advantages to the medicine and pharmaceutical industry. Moreover, more industry participants are utilizing and adopting cutting-edge Technology has grown substantially. Major players in the Fibromyalgia Treatments market, including Pfizer, AstraZeneca, GlaxoSmithKline, Astellas Pharma, F. Hoffmann-La Roche AG, SANOFI, Johnson & Johnson Services Inc, and others, are attempting to expand market share and demand by investing in R&D operations to produce sustainable and affordable solutions.
Aptinyx Inc. is a biopharma firm discovering and developing novel medicines for difficult brain and nervous system ailments. Aptinyx offers a proven platform for identifying unique drugs that act via a new mechanism: regulating the receptor for NMDA to improve nerve cell communication pathways. This mechanism applies to a variety of CNS diseases. They aim to move our most promising therapies into clinical trials for diseases with significant unmet medical needs as soon as possible. Aptinyx Inc. reported the findings of the Phase 2b study examining the impact of NYX-2925 in fibromyalgia patients in August 2022. On the primary objective of the research, which measured an improvement from a base in daily mean pain on the numerical rating scale (NRS) throughout week 12, NYX-2925 failed to achieve a statistically important difference from the placebo.
Astellas Pharma, Inc. is a pharmaceutical company studying, creating, manufacturing, importing, and exporting. Kenji Yamanouchi created the firm in April 1923, and it has its headquarters in Tokyo, Japan. Astellas Pharma Inc. announced in July 2020 that it had been given funding from the NIDA), a component of NIH in the United States, to assist in funding two phase 1 clinical studies to examine the safety and effectiveness of ASP8062.
Key Companies in the market of Fibromyalgia Treatments include
Fibromyalgia Treatments Industry Developments
August 2022:Aptinyx Inc. reported the findings of a Phase 2b study examining the impact of NYX-2925 in fibromyalgia patients in August 2022. On the primary objective of the research, which measured an improvement from a base in daily mean pain on the numerical rating scale (NRS) throughout week 12, NYX-2925 failed to achieve a statistically important difference from the placebo.
February 2022:Wet cupping therapy (WCT), a novel treatment for fibromyalgia, will be explored by Karabuk University in February 2022 in collaboration with Saglik Bilimleri College and SULEYMAN ERSOY.
July 2020:Astellas Pharma Inc. announced in July 2020 that it had been given funding from NIDA, a component of NIH in the United States, to assist in funding two phase 1 clinical studies.
Antidepressants
Antiepileptic
Muscle Relaxants
Others
Hospital
Clinic
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 1.1 Billion |
| Market Size 2023 | USD 1.14 Billion |
| Market Size 2032 | USD 1.59 Billion |
| Compound Annual Growth Rate (CAGR) | 4.2% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Treatment, End-User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Pfizer, AstraZeneca, GlaxoSmithKline, Astellas Pharma, F. Hoffmann-La Roche AG, SANOFI, Johnson & Johnson Services Inc |
| Key Market Opportunities | Rising potential markets |
| Key Market Dynamics | Soft fibromyalgia therapy is used for its comfort and ability to cure numerous eye disorders. |
Fibromyalgia Treatments Market Highlights:
Frequently Asked Questions (FAQ) :
The Fibromyalgia Treatments market size was valued at USD 1.1 Billion in 2022.
The market is projected to grow and expand at a CAGR of 4.2% during the projected timeframe.
North America had the largest share of the market
The key players in the Fibromyalgia Treatments market are Pfizer, AstraZeneca, GlaxoSmithKline, Astellas Pharma, F. Hoffmann-La Roche AG, SANOFI, and Johnson & Johnson Services Inc.
Antiepileptic dominated the market in 2022.
Hospitals have the largest share of the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
